SITE015-0260

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE015 (POL) (Dr. Ito) · consented 2022-12-28

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-04 (study day 56); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-17 (study day 69); relationship: not assessed; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-13 (study day 157); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 209); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 285); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 290); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 343); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.